Endometrial hyperplasia and the risk of progression to carcinoma

Maturitas

Volumn 63, Issue 1, 2009, Pages 39-44

  Lacey Jr , James V ^a   Chia, Victoria M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer precursor; Complex atypical hyperplasia; Progression risk; Uterine cancer; WHO

Indexed keywords

BIOLOGICAL MARKER;

CANCER GROWTH; CANCER RISK; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; DISEASE CLASSIFICATION; DISEASE SEVERITY; ENDOMETRIUM BIOPSY; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; HUMAN; HYSTERECTOMY; REPRODUCIBILITY; REVIEW; UTERUS BLEEDING; WORLD HEALTH ORGANIZATION;

CARCINOMA; DISEASE PROGRESSION; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; PRECANCEROUS CONDITIONS; RISK; UTERINE HEMORRHAGE;

EID: 67349101671     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2009.02.005     Document Type: Review

References (58)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
2. Fiorelli J.L., Herzog T.J., and Wright J.D. Current treatment strategies for endometrial cancer. Expert Rev Anticancer Ther 8 (2008) 1149-1157
3. Bakkum-Gamez J.N., Gonzalez-Bosquet J., Laack N.N., Mariani A., and Dowdy S.C. Current issues in the management of endometrial cancer. Mayo Clin Proc 83 (2008) 97-112
4. Fraser I.S., Critchley H.O., and Munro M.G. Abnormal uterine bleeding: getting our terminology straight. Curr Opin Obstet Gynecol 19 (2007) 591-595
5. Xie X., Lu W.G., Ye D.F., Chen H.Z., and Fu Y.F. The value of curettage in diagnosis of endometrial hyperplasia. Gynecol Oncol 84 (2002) 135-139
6. Dijkhuizen F.P., Mol B.W., Brolmann H.A., and Heintz A.P. The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis. Cancer 89 (2000) 1765-1772
7. Kondo E., Tabata T., Koduka Y., et al. What is the best method of detecting endometrial cancer in outpatients?-endometrial sampling, suction curettage, endometrial cytology. Cytopathology 19 (2008) 28-33
8. Clark T.J., Mann C.H., Shah N., Khan K.S., Song F., and Gupta J.K. Accuracy of outpatient endometrial biopsy in the diagnosis of endometrial cancer: a systematic quantitative review. BJOG 109 (2002) 313-321
9. Kipp B.R., Medeiros F., Campion M.B., et al. Direct uterine sampling with the Tao brush sampler using a liquid-based preparation method for the detection of endometrial cancer and atypical hyperplasia: a feasibility study. Cancer 114 (2008) 228-235
10. Langer R.D., Pierce J.J., O'Hanlan K.A., et al. Transvaginal ultrasonography compared with endometrial biopsy for the detection of endometrial disease. Postmenopausal Estrogen/Progestin Interventions Trial. N Engl J Med 337 (1997) 1792-1798
11. Espindola D., Kennedy K.A., and Fischer E.G. Management of abnormal uterine bleeding and the pathology of endometrial hyperplasia. Obstet Gynecol Clin North Am 34 (2007) 717-737
12. Montgomery B.E., Daum G.S., and Dunton C.J. Endometrial hyperplasia: a review. Obstet Gynecol Surv 59 (2004) 368-378
13. Karlsson B., Granberg S., Wikland M., et al. Transvaginal ultrasonography of the endometrium in women with postmenopausal bleeding-a Nordic multicenter study. Am J Obstet Gynecol 172 (1995) 1488-1494
14. Silverberg S.G. Problems in the differential diagnosis of endometrial hyperplasia and carcinoma. Mod Pathol 13 (2000) 309-327
15. Marsden D.E., and Hacker N.F. Optimal management of endometrial hyperplasia. Best Pract Res Clin Obstet Gynaecol 15 (2001) 393-405
16. Montz F.J., Bristow R.E., Bovicelli A., Tomacruz R., and Kurman R.J. Intrauterine progesterone treatment of early endometrial cancer. Am J Obstet Gynecol 186 (2002) 651-657
17. Randall T.C., and Kurman R.J. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol 90 (1997) 434-440
18. Scully R.E., Bonfiglio T.A., Kurman R.J., Silverberg S.G., and Wilkinson E.J. Uterine corpus. World Health Organization: histological typing of female genital tract tumors (1994), Spinger-Verlag, New York p. 13-31
19. Zaino R.J. Endometrial hyperplasia: is it time for a quantum leap to a new classification?. Int J Gynecol Pathol 19 (2000) 314-321
20. Bergeron C., Nogales F.F., Masseroli M., et al. A multicentric European study testing the reproducibility of the WHO classification of endometrial hyperplasia with a proposal of a simplified working classification for biopsy and curettage specimens. Am J Surg Pathol 23 (1999) 1102-1108
21. Kendall B.S., Ronnett B.M., Isacson C., et al. Reproducibility of the diagnosis of endometrial hyperplasia, atypical hyperplasia, and well-differentiated carcinoma. Am J Surg Pathol 22 (1998) 1012-1019
22. Skov B.G., Broholm H., Engel U., et al. Comparison of the reproducibility of the WHO classifications of 1975 and 1994 of endometrial hyperplasia. Int J Gynecol Pathol 16 (1997) 33-37
23. Sherman M.E., Ronnett B.M., Ioffe O.B., et al. Reproducibility of biopsy diagnoses of endometrial hyperplasia: evidence supporting a simplified classification. Int J Gynecol Pathol 27 (2008) 318-325
24. Amant F., Moerman P., Neven P., Timmerman D., Van Limbergen E., and Vergote I. Endometrial cancer. Lancet 366 (2005) 491-505
25. Baanders-van Halewyn E.A., Blankenstein M.A., Thijssen J.H., de Ridder C.M., and de Waard F. A comparative study of risk factors for hyperplasia and cancer of the endometrium. Eur J Cancer Prev 5 (1996) 105-112
26. Kreiger N., Marrett L.D., Clarke E.A., Hilditch S., and Woolever C.A. Risk factors for adenomatous endometrial hyperplasia: a case-control study. Am J Epidemiol 123 (1986) 291-301
27. Farquhar C.M., Lethaby A., Sowter M., Verry J., and Baranyai J. An evaluation of risk factors for endometrial hyperplasia in premenopausal women with abnormal menstrual bleeding. Am J Obstet Gynecol 181 (1999) 525-529
28. Weber A.M., Belinson J.L., and Piedmonte M.R. Risk factors for endometrial hyperplasia and cancer among women with abnormal bleeding. Obstet Gynecol 93 (1999) 594-598
29. Epplein M., Reed S.D., Voigt L.F., Newton K.M., Holt V.L., and Weiss N.S. Risk of complex and atypical endometrial hyperplasia in relation to anthropometric measures and reproductive history. Am J Epidemiol 168 (2008) 563-570
30. Gredmark T., Kvint S., Havel G., and Mattsson L.A. Adipose tissue distribution in postmenopausal women with adenomatous hyperplasia of the endometrium. Gynecol Oncol 72 (1999) 138-142
31. Ricci E., Moroni S., Parazzini F., et al. Risk factors for endometrial hyperplasia: results from a case-control study. Int J Gynecol Cancer 12 (2002) 257-260
32. Anastasiadis P.G., Skaphida P.G., Koutlaki N.G., Galazios G.C., Tsikouras P.N., and Liberis V.A. Descriptive epidemiology of endometrial hyperplasia in patients with abnormal uterine bleeding. Eur J Gynaecol Oncol 21 (2000) 131-134
33. Pennant S., Manek S., and Kehoe S. Endometrial atypical hyperplasia and subsequent diagnosis of endometrial cancer: a retrospective audit and literature review. J Obstet Gynaecol 28 (2008) 632-633
34. Trimble C.L., Kauderer J., Zaino R., et al. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer 106 (2006) 812-819
35. Shutter J., and Wright Jr. T.C. Prevalence of underlying adenocarcinoma in women with atypical endometrial hyperplasia. Int J Gynecol Pathol 24 (2005) 313-318
36. Sorosky J.I. Endometrial cancer. Obstet Gynecol 111 (2008) 436-447
37. Lowe M.P., Cooper B.C., Sood A.K., Davis W.A., Syrop C.H., and Sorosky J.I. Implementation of assisted reproductive technologies following conservative management of FIGO grade I endometrial adenocarcinoma and/or complex hyperplasia with atypia. Gynecol Oncol 91 (2003) 569-572
38. Allison K.H., Tenpenny E., Reed S.D., Swisher E.M., and Garica R.L. Immunohistochemical markers in endometrial hyperplasia: is there a panel with promise? A review. Appl Immunohistochem Mol Morphol 16 (2008) 329-343
39. Pettersson B., Adami H.O., Lindgren A., and Hesselius I. Endometrial polyps and hyperplasia as risk factors for endometrial carcinoma. A case-control study of curettage specimens. Acta Obstet Gynecol Scand 64 (1985) 653-659
40. Colgan T.J., Norris H.J., Foster W., Kurman R.J., and Fox C.H. Predicting the outcome of endometrial hyperplasia by quantitative analysis of nuclear features using a linear discriminant function. Int J Gynecol Pathol 1 (1983) 347-352
41. Kurman R.J., Kaminski P.F., and Norris H.J. The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients. Cancer 56 (1985) 403-412
42. Ortner A., Mikuz G., and Jerabek R. Study of prior biopsies of endometrial cancer patients and controls. Cancer Detect Prev 4 (1981) 475-480
43. Sherman A.I., and Brown S. The precursors of endometrial carcinoma. Am J Obstet Gynecol 135 (1979) 947-956
44. Feldman S., Cook E.F., Harlow B.L., and Berkowitz R.S. Predicting endometrial cancer among older women who present with abnormal vaginal bleeding. Gynecol Oncol 56 (1995) 376-381
45. Lacey Jr. J.V., Ioffe O.B., Ronnett B.M., et al. Endometrial carcinoma risk among women diagnosed with endometrial hyperplasia: the 34-year experience in a large health plan. Br J Cancer 98 (2008) 45-53
46. Mutter G.L., Zaino R.J., Baak J.P., Bentley R.C., and Robboy S.J. Benign endometrial hyperplasia sequence and endometrial intraepithelial neoplasia. Int J Gynecol Pathol 26 (2007) 103-114
47. Lacey Jr. J.V., Mutter G.L., Ronnett B.M., et al. PTEN expression in endometrial biopsies as a marker of progression to endometrial carcinoma. Cancer Res 68 (2008) 6014-6020
48. Mutter G.L., Lin M.C., Fitzgerald J.T., et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 92 (2000) 924-930
49. Baak J.P., Orbo A., van Diest P.J., et al. Prospective multicenter evaluation of the morphometric D-score for prediction of the outcome of endometrial hyperplasias. Am J Surg Pathol 25 (2001) 930-935
50. Orbo A., Baak J.P., Kleivan I., et al. Computerised morphometrical analysis in endometrial hyperplasia for the prediction of cancer development. A long-term retrospective study from northern Norway. J Clin Pathol 53 (2000) 697-703
51. Lacey Jr. J.V., Mutter G.L., Nucci M.R., et al. Risk of subsequent endometrial carcinoma associated with endometrial intraepithelial neoplasia classification of endometrial biopsies. Cancer 113 (2008) 2073-2081
52. Horowitz N., Pinto K., Mutch D.G., et al. Microsatellite instability, MLH1 promoter methylation, and loss of mismatch repair in endometrial cancer and concomitant atypical hyperplasia. Gynecol Oncol 86 (2002) 62-68
53. Orbo A., Nilsen M.N., Arnes M.S., Pettersen I., and Larsen K. Loss of expression of MLH1, MSH2, MSH6, and PTEN related to endometrial cancer in 68 patients with endometrial hyperplasia. Int J Gynecol Pathol 22 (2003) 141-148
54. Duggan B.D., Felix J.C., Muderspach L.I., Tourgeman D., Zheng J., and Shibata D. Microsatellite instability in sporadic endometrial carcinoma. J Natl Cancer Inst 86 (1994) 1216-1221
55. Lagarda H., Catasus L., Arguelles R., Matias-Guiu X., and Prat J. K-ras mutations in endometrial carcinomas with microsatellite instability. J Pathol 193 (2001) 193-199
56. Lax S.F., Kendall B., Tashiro H., Slebos R.J., and Hedrick L. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 88 (2000) 814-824
57. Mirabelli-Primdahl L., Gryfe R., Kim H., et al. Beta-catenin mutations are specific for colorectal carcinomas with microsatellite instability but occur in endometrial carcinomas irrespective of mutator pathway. Cancer Res 59 (1999) 3346-3351
58. Moreno-Bueno G., Hardisson D., Sanchez C., et al. Abnormalities of the APC/beta-catenin pathway in endometrial cancer. Oncogene 21 (2002) 7981-7990